Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Baxter International Inc    BAX

News SummaryMost relevantAll newsSector newsTweets 

Baxter International Inc. : Baxter's Investigational Hemophilia Treatment Yields Positive Results

share with twitter share with LinkedIn share with facebook
share via e-mail
12/10/2012 | 03:34pm CEST
    By Saabira Chaudhuri 

Baxter International Inc. (BAX) said results from a study evaluating its investigational treatment for patients with hemophilia B were positive.

The medical product company's BAX 326--its investigational recombinant factor IX protein for the treatment and prophylaxis of bleeding episodes for patients with hemophilia B over 12 years of age--was recently granted orphan-drug designation by the U.S. Food and Drug Administration.

"With only one recombinant protein currently available to treat hemophilia B, it was important to focus research efforts on finding another option for patients with this debilitating disease," Lead Investigator Jerzy Windyga said. "In this study, more than 40 percent of patients using BAX 326 as a prophylactic treatment experienced no bleeds, an important finding given the potentially harmful impact of bleeding episodes for patients."

The study investigated the efficacy and safety of BAX 326 in 73 previously treated patients with severe or moderately severe hemophilia B.

Baxter noted that hemophilia B is the second most common type of hemophilia--also known as Christmas disease--and is the result of insufficient amounts of clotting factor IX, a naturally occurring protein in blood that controls bleeding. The company added that about 25,000 people world-wide, including more than 4,000 in the U.S., have been diagnosed with hemophilia B.

Baxter's profits have improved for more than a year on strong demand for its hemophilia and immunodeficiency products. Its bottom line has been less pressured by the slowdown in health-care spending, compared with some peers, because Baxter focuses on medical devices and pharmaceuticals used to treat life-threatening ailments and injuries.

In October, Baxter said its third-quarter earnings rose 1.2% as the company's margins improved, though sales were short of its prior guidance.

Shares closed Friday at $65.07 and were inactive in recent premarket trading. The stock has risen 32% so far this year.

Write to Saabira Chaudhuri at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
05/23 BAXTER INTERNATIONAL : Presents Data at ISPOR Annual Meeting with Focus on Helpi..
05/19 BAXTER INTERNATIONAL : Commonwealth Fund President, David Blumenthal, MD, MPP, N..
05/18 BAXTER INTERNATIONAL : to Present at the Goldman Sachs 38th Annual Healthcare Co..
05/18 BAXTER INTERNATIONAL : Launches New AK 98 Hemodialysis System Designed to Help P..
05/16 BAXTER INTERNATIONAL INC. : (Baxter); Located in Deerfield, IL
05/12 What happens to corporate crime cases with the FBI in flux?
05/11 BAXTER INTERNATIONAL : Raises Quarterly Dividend
05/11 BAXTER INTERNATIONAL : Achieves Regulatory Milestone for New Peritoneal Dialysis..
05/11 INSIDER TRADING ACTIVITY BAXTER INTE : BAX) – Director Sold 3,760 shares o..
05/10 INSIDER TRADING ACTIVITY BAXTER INTE : BAX) – SVP Sold 130,732 shares of S..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
05/23DJFirms Persuade SEC on Profit Metric -- WSJ
05/22DJCompanies Are Winning the Battle Over Adjusted Earnings
05/16 Earnings drag on European shares, though Vodafone lifts telcos
05/09 French outbound M&A driven to decade high by big deals
05/05 Pearson rally, miners help FTSE surge to strongest week since March
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
05/23 Baxter finance chief says business is good, company will be "incredibly disci..
05/22 Tracking Tweedy Browne Portfolio - Q1 2017 Update
05/21 Tracking Dan Loeb's Third Point Portfolio - Q1 2017 Update
05/18 Baxter launches new hemodialysis system
05/16 Premarket analyst action - healthcare
Financials ($)
Sales 2017 10 363 M
EBIT 2017 1 627 M
Net income 2017 1 169 M
Finance 2017 53,7 M
Yield 2017 0,96%
P/E ratio 2017 29,66
P/E ratio 2018 24,98
EV / Sales 2017 3,03x
EV / Sales 2018 2,86x
Capitalization 31 489 M
More Financials
Duration : Period :
Baxter International Inc Technical Analysis Chart | BAX | US0718131099 | 4-Traders
Full-screen chart
Technical analysis trends BAXTER INTERNATIO...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 16
Average target price 59,5 $
Spread / Average Target 2,7%
Consensus details
EPS Revisions
More Estimates Revisions
José E. Almeida Chairman, President & Chief Executive Officer
Scott Pleau Vice President-Operations
James K. Saccaro Chief Financial Officer & Vice President
Paul E. Martin Chief Information Officer & Vice President
Marcus Schabacker Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC17.91%114 973
C R BARD INC37.25%22 251
TERUMO CORP3.01%14 795
More Results